Patterns of Outcome Following Recurrence in Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Long Follow-up From a Single Centre
| العنوان: | Patterns of Outcome Following Recurrence in Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Long Follow-up From a Single Centre |
|---|---|
| المؤلفون: | Shireen Kassam, Silvia Montoto, Andrew Wilson, Janet Matthews, Kim Last, T. Andrew Lister, Ama Z S Rohatiner |
| المصدر: | Blood. 114:2921-2921 |
| بيانات النشر: | American Society of Hematology, 2009. |
| سنة النشر: | 2009 |
| مصطلحات موضوعية: | medicine.medical_specialty, Univariate analysis, business.industry, medicine.medical_treatment, Immunology, Cell Biology, Hematology, medicine.disease, Biochemistry, Comorbidity, Gastroenterology, Lymphoma, Surgery, Radiation therapy, Regimen, Internal medicine, medicine, Rituximab, Stage (cooking), business, Diffuse large B-cell lymphoma, medicine.drug |
| الوصف: | Abstract 2921 Poster Board II-897 Background: Despite improvements in outcome of patients (pts.) with DLBCL, the prognosis for those who relapse after first-line treatment remains very poor. This retrospective analysis reports outcome of pts. with DLBCL treated before the routine use of Rituximab, with a median (med.) follow-up of 12 years. Patients and Methods: Between 1985 and 2003, 461 pts. were diagnosed with DLBCL at SBH. 384/461 (83%, male: 208, med. age: 60 years, range 17-95) were treated with curative intent (CI) and form the basis of this analysis. Those with primary CNS or primary mediastinal B-cell lymphoma and HIV +ve pts. were excluded. Histology at diagnosis included 31 pts. with ‘composite' lymphoma (29 follicular [FL], 1 lymphoplasmacytic, 1 ‘MALT') and 17 with ‘discordant' lymphoma (all FL).The majority, 142 (37%), had Stage IV disease, 99 (26%) stage I, 88 (23%) stage II and 55 (14%) stage III. The IPI score (ascribed retrospectively) was low-risk in 189 (49%), low-intermediate (int.) in 110 (29%), high-int. in 64 (17%) and high-risk in 21 (5%). 354/384 (92%) received an anthracycline-containing regimen, according to protocols in use at the time. 30 pts. (8%) with localised disease received radiotherapy alone. Prior to 2001, all pts. received prophylactic intra-thecal methotrexate; subsequently, only those at high risk for CNS relapse did so. Results: CR/CRu was achieved in 240/384 pts. (63%) and PR in 67 (17%). 53 (14%) did not respond (NR) and 24 (6%) died of causes related to initial therapy. Overall survival (OS) correlated with outcome to therapy (CR/CRu vs PR vs NR, p Conclusion: Despite the curative potential of HDT, these data confirm that recurrence of DLBCL, in an unselected patient population, carries an appalling prognosis. Improving initial therapy is therefore crucial. In pts. in whom conventional 2nd-line therapy has failed, it is entirely justifiable to evaluate experimental therapies. Disclosures: No relevant conflicts of interest to declare. |
| تدمد: | 1528-0020 0006-4971 |
| DOI: | 10.1182/blood.v114.22.2921.2921 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_________::d35672a5ff3f2936cdfe7adfdb7b73bc https://doi.org/10.1182/blood.v114.22.2921.2921 |
| رقم الانضمام: | edsair.doi...........d35672a5ff3f2936cdfe7adfdb7b73bc |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15280020 00064971 |
|---|---|
| DOI: | 10.1182/blood.v114.22.2921.2921 |